Grifols, S.A. (GRF.MC)
Chart Events
Performance Outlook
| Previous Close | 13.27 |
| Open | 13.14 |
| Bid | 13.64 x 0 |
| Ask | 13.58 x 0 |
| Day's Range | 13.03 - 13.80 |
| 52 Week Range | 7.82 - 20.28 |
| Volume | |
| Avg. Volume | 1,742,619 |
| Market Cap | 8.203B |
| Beta (5Y Monthly) | 0.42 |
| PE Ratio (TTM) | 136.45 |
| EPS (TTM) | 0.10 |
| Earnings Date | Feb 28, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jun 03, 2021 |
| 1y Target Est | 18.71 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for GRF.MC
Related Research
- Reuters
Grifols considers selling 2 bln euros worth of assets to cut debt, Cinco Dias says
Spanish pharmaceutical company Grifols considers selling assets worth about 2 billion euros ($2.12 billion) to cut its debt, Cinco Dias reported on Wednesday, citing unidentified financial sources. The company may sell its Chinese business and its diagnoses unit, Cinco Dias reported. A spokesperson for the company declined to comment though in November Grifols said it was committed to reducing its 9.4 billion net debt.
- PR Newswire
Grifols receives FDA clearance for AlphaID™ At Home, the first free service for U.S. consumers to determine their risk for alpha-1
Grifols (MCE: GRF) (MCE:GRF.P) (NASDAQ:GRFS), a global leader in plasma-derived medicines and innovative diagnostic solutions, today announced that its AlphaID™ At Home Genetic Health Risk Service, the first-ever free direct-to-consumer program in the U.S. to screen for genetic risk of alpha1-antitrypsin deficiency (alpha-1), has been cleared by the U.S. Food and Drug Administration (FDA).
- Insider Monkey
10 Best Pharma Stocks To Buy Now
In this article, we discuss the 10 best pharma stocks to buy now. If you want to see more stocks in this selection, check out the 5 Best Pharma Stocks To Buy Now. With a compound annual growth rate (CAGR) of 9.1%, the global pharmaceuticals industry is projected to expand to $1587.1 billion in 2022 from […]
